Table 1 Clinical characteristics at the time of biopsy and follow-up in 218 pediatric patients with IgA nephropathy
From: Validation of the Oxford classification of IgA nephropathy for pediatric patients from China
| Â | Current study | Oxford study (Children) | Shima et al. [19] |
|---|---|---|---|
At time of biopsy | n = 218 | n = 59 | n = 161 |
 Age (years) | 14 (2–17.9) | 13 (4–17.9) | 11.7(3.6-19.4) |
 Female | 35% | 25% | 37% |
 Hypertensive before biopsy | 6.5% | NA | NA |
 MAP (mm Hg) | 88 ± 11 | 84 ± 10 | 79 ± 11 |
 eGFR (ml/min per 1.73 m2) | 134 ± 42 | 120 ± 43 | 103 ± 30 |
 Proteinuria (g/day) | 1.5(0.5-8.0) | 2 (0.5-7.8) | 0.7 (0.0–13.7) |
 Previous macroscopic hematuria | 57% | 60% | 66% |
Follow-up | |||
 Duration of follow-up (months) | 56(12–182) | 62 (20–268) | 54 (12–170) |
 50% decline in eGFR or ESRD | 12.4% | NA | NA |
 MAP (mm Hg) | 86 ± 10 | 86 ± 8 | NA |
 Proteinuria (g/day) | 0.6 (0.1-4.9) | 0.9 (0.1–7.0) | NA |
 Immunosuppression | 56% | 48% | 16% |
 Prednisone | 51% | 48% | 16% |
 Others | 28.6% | 17% | 11% |
 Treated with RASB | 61.5% | 56% | NA |